Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The G1 restriction point is critical for regulating the cell cycle and is controlled by the Rb pathway (CDK4/6-cyclin D1-Rb-p16/ink4a). This pathway is important because of its inactivation in a majority of human tumors. Transition through the restriction point requires phosphorylation of retinoblastoma protein (Rb) by CDK4/6, which are highly validated cancer drug targets. We present the identification and characterization of a potent CDK4/6 inhibitor, LY2835219. LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells. In vivo target inhibition studies show LY2835219 is a potent inhibitor of Rb phosphorylation, induces a complete cell cycle arrest and suppresses expression of several Rb-E2F-regulated proteins 24 hours after a single dose. Oral administration of LY2835219 inhibits tumor growth in human tumor xenografts representing different histologies in tumor-bearing mice. LY2835219 is effective and well tolerated when administered up to 56 days in immunodeficient mice without significant loss of body weight or tumor outgrowth. In calu-6 xenografts, LY2835219 in combination with gemcitabine enhanced in vivo antitumor activity without a G1 cell cycle arrest, but was associated with a reduction of ribonucleotide reductase expression. These results suggest LY2835219 may be used alone or in combination with standard-of-care cytotoxic therapy. In summary, we have identified a potent, orally active small-molecule inhibitor of CDK4/6 that is active in xenograft tumors. LY2835219 is currently in clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“The reasons for reduced hematologic toxicity and other observed non-hematologic toxicities are under active investigation but may be related to a greater selectivity for CDK4 over CDK6 with abemaciclib (88), its greater relative potency and potential to target CDK9 (Table 1), and/or its distribution into the central nervous system (93).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [88]
In the citing paper
“In vitro studies using cyclin D1/CDK4 and various cyclin D/CDK6 kinases determined that both abemaciclib and ribociclib are more potent against CDK4 than CDK6 (Gelbert et al., 2014; Tripathy et al., 2017) (Table 1).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Gelbert et al., 2014
In the citing paper
“In such assays, abemaciclib also has modest activity, relative to its CDK4 inhibitory activity, against cyclin T1/CDK9, cyclin E2/CDK2, p25/CDK5 and p35/CDK5 (Gelbert et al., 2014) (Table 2).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Gelbert et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Sustained proliferative capacity is a hallmark of cancer [1].”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317 · cited 1×
“The retinoblastoma protein (Rb) is a tumor suppressor that inhibits proliferation through binding to and suppressing the activity of the E2F family of transcription factors [5].”
BackgroundTo cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
A Restriction Point for Control of Normal Animal Cell Proliferation
Pardee, A. B. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1286 · Cited by 1,415 · cited 1×
“originally described as the point where cell proliferation becomes independent of mitogens and growth factors [2], and the normal function of the restriction point is essential for maintaining control of cellular proliferation [3, 4].”
BackgroundFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“recently reported a CDK4/6 inhibitor, PD 0332991, possessing improved potency and selectivity over previous inhibitors [22].”
BackgroundLundberg, A. S., & Weinberg, R. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.753 · Cited by 1,067 · cited 2×
“Active CDK4/6 then phosphorylates Rb, partially relieving suppression of E2F to allow expression of genes required for passage through the restriction point [7, 8].”
BackgroundHarbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036 · cited 1×
“The importance of the pathway in tumorigenesis and recent success developing small molecule kinase inhibitors, make CDK4/6 a highly validated cancer drug target [33, 34].”
BackgroundThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911 · cited 1×
“Both p16/ink4a and Rb act as tumor suppressors and are found to be functionally inactivated in numerous tumor types [19, 20].”
BackgroundCyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778 · cited 4×
“originally described as the point where cell proliferation becomes independent of mitogens and growth factors [2], and the normal function of the restriction point is essential for maintaining control of cellular proliferation [3, 4].”
BackgroundInfluentialSubtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735 · cited 1×
“CDK4 is amplified or overexpressed in several tumors, including soft tissue sarcomas, glioblastoma, and melanoma [15–18].”
BackgroundSandler, A. B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M. C., Gregor, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.122 · Cited by 712 · cited 1×
“LY2835219 can be combined with the cytotoxic drug gemcitabine, approved to treat several types of tumors, including lung cancer [44].”
BackgroundTargeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674 · cited 1×
“Acquired drug resistance can occur due to prolonged treatment with kinase inhibitors [29].”
BackgroundThe management of brain metastases
Patchell, R. A. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00105-1 · Cited by 654
Ishida, S., Huang, E., Zuzan, H., Spang, R., Leone, G., West, M., & Nevins, J. R. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.14.4684-4699.2001 · Cited by 596 · cited 1×
“Phosphorylation of Rb by CDK4/6 also leads to transcription of genes involved in cell cycle-independent activities including signal transduction, DNA repair transcriptional control, and mRNA processing [9].”
BackgroundKitagawa, M., Higashi, H., Jung, H. K., Suzuki-Takahashi, I., Ikeda, M., Tamai, K., Kato, J., Segawa, K., Yoshida, E., Nishimura, S., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01097.x · Cited by 589 · cited 1×
“Cellular inhibition of CDK4/6 was determined by monitoring Rb phosphorylation at serine 780 (pRb), which is specific for CDK4/6 [24].”
MethodAnders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543 · cited 2×
“CDK4/6 have also recently been shown to phosphorylate other proteins, including FOXM1 and E2F1 [10, 11], which modulate additional cellular processes that are cell cycle -independent.”
BackgroundHorowitz, J. M., Park, S. H., Bogenmann, E., Cheng, J. C., Yandell, D. W., Kaye, F. J., Minna, J. D., Dryja, T. P., & Weinberg, R. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2775 · Cited by 530 · cited 1×
“Both p16/ink4a and Rb act as tumor suppressors and are found to be functionally inactivated in numerous tumor types [19, 20].”
BackgroundGoto, H., Kosako, H., Tomono, Y., Ajiro, K., Fujita, M., Sakurai, M., Okawa, K., Iwamatsu, A., Okigaki, T., Takahashi, T., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25543 · Cited by 457
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · cited 2×
“Significantly, H460 contains activating KRAS mutation in codon 61, like calu-6, and shows an attenuated response to LY2835219 (25 mg/kg dose Table 2), consistent with a role for KRAS modifying response to CDK4/6 inhibitors [48, 49].”
BackgroundResultThe Restriction Point of the Cell Cycle
Blagosklonny, M. V., & Pardee, A. B. (2002) · Cell Cycle · doi:10.4161/cc.1.2.108 · Cited by 412 · cited 1×
“originally described as the point where cell proliferation becomes independent of mitogens and growth factors [2], and the normal function of the restriction point is essential for maintaining control of cellular proliferation [3, 4].”
BackgroundBrain metastases as preventive and therapeutic targets
Steeg, P. S., Camphausen, K. A., & Smith, Q. R. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3053 · Cited by 363
Bepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., & Simon, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1101 · Cited by 333 · cited 1×
“In vitro and in vivo chemosensitivity to gemcitabine strongly correlates to RRM1 expression [45, 46], consistent with the modulation of RRM1 seen for LY2835219 and gemcitabine in our experiments.”
BackgroundDonnellan, R., & Chetty, R. (1998) · Molecular Pathology · doi:10.1136/mp.51.1.1 · Cited by 327 · cited 1×
“In mantle cell lymphoma (MCL), cyclin D1 is upregulated by the (11;14) chromosomal translocation seen in this tumor, and cyclin D1 is overexpressed in many breast, head and neck, prostate, and melanoma tumors [12, 13].”
BackgroundThe genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302 · cited 1×
“CDK4 is amplified or overexpressed in several tumors, including soft tissue sarcomas, glioblastoma, and melanoma [15–18].”
BackgroundDavidson, J. D., Ma, L., Flagella, M., Geeganage, S., Gelbert, L. M., & Slapak, C. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3363 · Cited by 280 · cited 1×
“In vitro and in vivo chemosensitivity to gemcitabine strongly correlates to RRM1 expression [45, 46], consistent with the modulation of RRM1 seen for LY2835219 and gemcitabine in our experiments.”
BackgroundSelf-citationKim, K.-T., Baird, K., Ahn, J.-Y., Meltzer, P., Lilly, M., Levis, M., & Small, D. (2005) · Blood · doi:10.1182/blood-2004-05-2006 · Cited by 234 · cited 1×
“Similarly, while activity against PIM1 was seen in biochemical assays, monitoring of the cell cycle in vitro and in vivo shows LY2835219 induces a G1 cell-cycle arrest, even in MV4-11 and Jeko-1 cells and xenografts, which express high levels of PIM1 [40–43].”
BackgroundFernàndez, V., Hartmann, E., Ott, G., Campo, E., & Rosenwald, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.019 · Cited by 211 · cited 1×
“In mantle cell lymphoma (MCL), cyclin D1 is upregulated by the (11;14) chromosomal translocation seen in this tumor, and cyclin D1 is overexpressed in many breast, head and neck, prostate, and melanoma tumors [12, 13].”
BackgroundRegulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control
Oelgeschläger, T. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10058 · Cited by 169 · cited 2×
“Activity against CDK9/cyclin T1 was seen (IC50=57 nmol/L); but did not translate to significant cellular CDK9 activity (inhibition of RNA polymerase C-terminal domain [Ser2] phosphorylation (pCTD) or a G2/M arrest in U2OS cells, Figure S1 and Table S1, Supplemental materials), possibly due to compensation by CDK7 [23].”
BackgroundBarton, K. L., Misuraca, K., Cordero, F., Dobrikova, E., Min, H. D., Gromeier, M., Kirsch, D. G., & Becher, O. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077639 · Cited by 162 · cited 2×
“Previously reported data that PD0332991 has efficacy in vivo without inhibition of p-Rb [47] also suggest low levels of inhibition of p-Rb may lead to antitumor activity in vivo.”
BackgroundResultFagan, R., Flint, K. J., & Jones, N. (1994) · Cell · doi:10.1016/s0092-8674(94)90522-3 · Cited by 160 · cited 2×
“CDK4/6 have also recently been shown to phosphorylate other proteins, including FOXM1 and E2F1 [10, 11], which modulate additional cellular processes that are cell cycle -independent.”
BackgroundLocation, location, location: The role of cyclin D1 nuclear localization in cancer
Gladden, A. B., & Diehl, J. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20613 · Cited by 136 · cited 1×
“In early G1, when conditions are favorable for proliferation, D-type cyclin levels increase through transcriptional and posttranscriptional mechanisms [6].”
BackgroundWang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134 · cited 5×
“2 a Activity of LY2835219 in colo-205 and MCF10A cells using a multiplexed assay measuring p-Rb serine 780 (green), cells in G1 (2 N DNA content, red) and total cell number (black). after 24-hour exposure LY2835219 shows a dose-dependent inhibition of p-Rb (ser780) and a corresponding sustained G1 arrest. bMV4-11 acut…”
BackgroundInfluentialTate, S. C., Cai, S., Ajamie, R. T., Burke, T., Beckmann, R. P., Chan, E. M., De Dios, A., Wishart, G. N., Gelbert, L. M., & Cronier, D. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2846 · Cited by 130
Self-citationGoswami, P. C., Roti Roti, J. L., & Hunt, C. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1500 · Cited by 122 · cited 1×
“Western blot analysis was performed using the three cellcycle-specific markers: p-Rb, a marker for CDK4/6 inhibition and a phenotypic marker for cells in G1; topisomerase II alpha (TopoIIα), a marker for cells in S phase [25]; and phosphohistone H3 serine 10 (pHH3), a marker for cells in M phase [26].”
MethodYu, J., Deshmukh, H., Payton, J. E., Dunham, C. P., Scheithauer, B. W., Tihan, T., Prayson, R. A., Guha, A., Bridge, J. A., Ferner, R. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1551 · Cited by 118 · cited 1×
“CDK4 is amplified or overexpressed in several tumors, including soft tissue sarcomas, glioblastoma, and melanoma [15–18].”
BackgroundIs Cyclin D1-CDK4 kinase a bona fide cancer target?
Malumbres, M., & Barbacid, M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.026 · Cited by 107
Constitutively activated FLT3 phosphorylates BAD partially through Pim‐1
Kim, K., Levis, M. J., & Small, D. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06225.x · Cited by 93 · cited 1×
“Similarly, while activity against PIM1 was seen in biochemical assays, monitoring of the cell cycle in vitro and in vivo shows LY2835219 induces a G1 cell-cycle arrest, even in MV4-11 and Jeko-1 cells and xenografts, which express high levels of PIM1 [40–43].”
BackgroundMerriman, R. L., Hertel, L. W., Schultz, R. M., Houghton, P. J., Houghton, J. A., Rutherford, P., Tanzer, L. R., Boder, G. B., & Grindey, G. B. (1996) · Investigational New Drugs · doi:10.1007/bf00194526 · Cited by 88 · cited 2×
“Administering the compounds together or in sequence had greater antitumor activity than the individual treatments and was equivalent to the maximum tolerated dose of gemcitabine (150 mg/kg) [31].”
BackgroundMethodRetinoblastoma Tumor Suppressor Targets dNTP Metabolism to Regulate DNA Replication
Angus, S. P., Wheeler, L. J., Ranmal, S. A., Zhang, X., Markey, M. P., Mathews, C. K., & Knudsen, E. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205911200 · Cited by 85 · cited 2×
“In addition to the cell cycle markers, we assessed the modulation of several Rb/E2F-regulated proteins that are the targets of cytotoxic drugs [28].”
BackgroundNew combination therapies with cell-cycle agents.
Deep, G., & Agarwal, R. (2008) · PubMed · Cited by 77
Cyclin-dependent kinase inhibitors move into Phase III
Guha, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3908 · Cited by 77 · cited 1×
“These recent results support the clinical potential for selective targeting of CDK4/6 in the treatment of cancer [35].”
ResultPelletier, E. M., Shim, B., Goodman, S., & Amonkar, M. M. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9601-0 · Cited by 74
Musgrove, E. A., Liuschkis, R., Cornish, A. L., Lee, C. S. L., Setlur, V., Seshadri, R., & Sutherland, R. L. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630420 · Cited by 71 · cited 1×
“Functional Rb protein is required for CDK4/6 to regulate the G1 restriction point; the mechanism of action for LY2835219 was further defined in breast cancer cell lines with and without functional Rb [27].”
BackgroundShapiro, G., Rosen, L. S., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Kulanthaivel, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2500 · Cited by 67
Self-citationde Vos, S., Krug, U. O., Hofmann, W., Pinkus, G. S., Swerdlow, S. H., Wachsman, W., Grogan, T. M., Said, J. W., & Koeffler, H. P. (2003) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200303000-00005 · Cited by 65
Zhu, Y., Hollmén, J., Räty, R., Aalto, Y., Nagy, B., Elonen, E., Kere, J., Mannila, H., Franssila, K., & Knuutila, S. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03931.x · Cited by 59 · cited 1×
“Similarly, while activity against PIM1 was seen in biochemical assays, monitoring of the cell cycle in vitro and in vivo shows LY2835219 induces a G1 cell-cycle arrest, even in MV4-11 and Jeko-1 cells and xenografts, which express high levels of PIM1 [40–43].”
BackgroundReifenberger, G., REIFENBERGER, J., Ichimura, K., & Collins, V. P. (1995) · PubMed · Cited by 55
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ct232 · Cited by 44
Self-citationDempsey, J. A., Chan, E. M., Burke, T. F., & Beckmann, R. P. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-122 · Cited by 16
Self-citationLin, X., Gelbert, L. M., Chu, S., Medina, D. L., Garcia-Paredes, C., & de Dios, A. (2007) · Cancer Research · Cited by 1
Self-citation
Research works printed but not linked: 1
- Hughes A (2006) CDK inhibitors in 3D: Problems with the drugs, their development plans or their linkage to disease? Gene Ther Mol Biol 10:41–54
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
“Abemaciclib prevents CDK 4 and 6 phosphorylation of the retinoblastoma tumor suppressor protein, thereby inducing G1 arrest and abrogating cell growth.(15) Preclinical evaluation demonstrated the antitumor activity of abemaciclib in an ER+/human epidermal growth factor receptor 2-negative (HER2−) breast cancer xenogra…”
BackgroundMatthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Metadata
- Authors
- Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., Neubauer, B. L., Young, J., Chan, E. M., Iversen, P., Cronier, D., Kreklau, E., & de Dios, A.
- Affiliations
- Eli Lilly (United States) (US)
- Eli Lilly (Spain) (ES)
- Eli Lilly (United Kingdom) (GB)
- Covance (United States) (US)
- Corresponding author
- Gelbert, Lawrence M.
- Venue
- Investigational New Drugs
- Published
- 2014-06-13
- Volume
- 32
- Issue
- 5
- Pages
- 825-837
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- PMC
- PMC4169866
- OpenAlex
- W1991601194
- Cited by
- 577
- References
- 52
- Citations by year
- 2026: 26 · 2025: 47 · 2024: 47 · 2023: 64 · 2022: 56 · 2021: 53 · 2020: 69 · 2019: 39 · 2018: 49 · 2017: 63 · 2016: 35 · 2015: 25 · 2014: 4
- FWCI
- 20.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Investigational New Drugs (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6 inhibitors, retinoblastoma protein phosphorylation, G1 cell cycle arrest, Rb/E2F pathway, gemcitabine combination therapy, oral antitumor activity, tumor xenografts, ribonucleotide reductase, small-molecule kinase inhibitors
- MeSH terms
- Gemcitabine, Aminopyridines, Animals, Antineoplastic Agents, Benzimidazoles, Deoxycytidine, Drug Therapy, Combination, Female, Humans, Neoplasms, Phosphorylation, Retinoblastoma Protein, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, G1 Phase Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.